Alan Garstka, MD
Cardiovascular Disease · Manchester, NHNPI 1770552853
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,766 of the $2,816 with a category attached, or 62.7%. Abbott accounts for 69.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $2,634 and has fallen 98.5% since, to $39 in 2022.
Across 61 payments — averaging $46.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Johnson & Johnson$154
- AstraZeneca$129
- Boehringer Ingelheim$124
- Boston Scientific$114
- Actelion Pharmaceuticals US, Inc.$112
- plus $222 from 7 others
What the payments were for
- Travel & lodging$1,05137%
- Food & beverage$1,76663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $1,962 |
| Johnson & Johnson | 10 | $154 |
| AstraZeneca | 7 | $129 |
| Boehringer Ingelheim | 6 | $124 |
| Boston Scientific | 5 | $114 |
| Actelion Pharmaceuticals US, Inc. | 8 | $112 |
| Novartis | 3 | $56 |
| Amgen | 3 | $53 |
| Pfizer | 2 | $35 |
| Abiomed | 1 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,816 in reported general payments places this provider in the 70th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Manchester
- Fahad GilaniManchester$418K
- Stephan HeoManchester$116K
- Robert CapodilupoManchester$85K
- Jeanney LewManchester$36K
- Jinu JohnManchester$12K
- Michelle OuelletteManchester$7K
- Patrick HickleManchester$5K
- Jeffrey BleakleyManchester$5K
- Tong ZhuManchester$4K
- Stephen HanlonManchester$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.